Evolus, Inc. (EOLS) stock
EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.00−0.07 (-0.99%)
Close on Nov 19, 2026Market cap $462.35MP/E –Yield –
Evolus free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Evolus's free cash flow for the twelve months ending Jun 30, 2026 was -$18.28M. For fiscal 2025 it was -$45.71M. The highest annual figure on record is -$13.22M in fiscal 2017.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$45.71M | – |
| FY2024 | Dec 31, 2024 | -$19.47M | – |
| FY2023 | Dec 31, 2023 | -$34.48M | – |
| FY2022 | Dec 31, 2022 | -$86.53M | – |
| FY2021 | Dec 31, 2021 | -$33.78M | – |
| FY2020 | Dec 31, 2020 | -$58.69M | – |
| FY2019 | Dec 31, 2019 | -$93.73M | – |
| FY2018 | Dec 31, 2018 | -$25.68M | – |
| FY2017 | Dec 31, 2017 | -$13.22M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.64M | – |
| Q1 FY2026 | Mar 31, 2026 | -$10.37M | – |
| Q4 FY2025 | Dec 31, 2025 | $11.35M | +159.7% |
| Q3 FY2025 | Sep 30, 2025 | -$15.62M | – |
| Q2 FY2025 | Jun 30, 2025 | -$25.48M | – |
| Q1 FY2025 | Mar 31, 2025 | -$15.95M | – |
| Q4 FY2024 | Dec 31, 2024 | $4.37M | +623.5% |
| Q3 FY2024 | Sep 30, 2024 | -$6.04M | – |
| Q2 FY2024 | Jun 30, 2024 | -$6.94M | – |
| Q1 FY2024 | Mar 31, 2024 | -$10.87M | – |
| Q4 FY2023 | Dec 31, 2023 | $604.00K | – |
| Q3 FY2023 | Sep 30, 2023 | -$953.00K | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.32M | – |
| Q1 FY2023 | Mar 31, 2023 | -$20.81M | – |
| Q4 FY2022 | Dec 31, 2022 | -$9.64M | – |
| Q3 FY2022 | Sep 30, 2022 | -$17.56M | – |
| Q2 FY2022 | Jun 30, 2022 | -$21.12M | -231.0% |
| Q1 FY2022 | Mar 31, 2022 | -$38.21M | – |
| Q4 FY2021 | Dec 31, 2021 | -$9.44M | – |
| Q3 FY2021 | Sep 30, 2021 | -$32.13M | – |
| Q2 FY2021 | Jun 30, 2021 | $16.12M | – |
| Q1 FY2021 | Mar 31, 2021 | -$8.34M | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.28M | – |
| Q3 FY2020 | Sep 30, 2020 | -$13.83M | – |
| Q2 FY2020 | Jun 30, 2020 | -$14.06M | – |
| Q1 FY2020 | Mar 31, 2020 | -$28.51M | – |
| Q4 FY2019 | Dec 31, 2019 | -$15.92M | – |
| Q3 FY2019 | Sep 30, 2019 | -$25.10M | – |
| Q2 FY2019 | Jun 30, 2019 | -$33.50M | – |
| Q1 FY2019 | Mar 31, 2019 | -$19.20M | – |
| Q4 FY2018 | Dec 31, 2018 | -$12.01M | – |
| Q3 FY2018 | Sep 30, 2018 | -$5.80M | – |
| Q4 FY2017 | Dec 31, 2017 | -$1.00M | – |
| Q3 FY2017 | Sep 30, 2017 | -$3.43M | – |
See a number that looks wrong?